Brussels, 2 April 2026
The Life Science Manufacturers Association (LSMA) has joined over 40 European organisations in calling for a dedicated and ambitious EU Biotech Act II to accelerate the scale-up of biomanufacturing across Europe. LSMA is a signatory to the joint position paper published today, which calls on the EU to close the gap between biotech innovation and industrial deployment.
LSMA represents the upstream manufacturers that make biomanufacturing possible. Its members supply the process inputs, single-use technologies, and advanced manufacturing systems without which biopharmaceutical, diagnostic, and advanced therapy production cannot function. As the EU works to strengthen its biomanufacturing base, this enabling layer must be part of the policy framework.
The EU Biotech Act I is a positive first step to support biotech innovation in healthcare. Converting that innovation into industrial-scale production across sectors requires further action. Regulatory fragmentation, insufficient incentive frameworks, and a persistent policy blind spot on enabling manufacturers to continue to hold back investment and scale-up. An ambitious Biotech Act II can address this by providing the market-facing coordination framework that upstream and downstream actors alike need to commit to European biomanufacturing capacity.
LSMA will continue to engage actively on the Biotech Act II to ensure that the upstream manufacturing perspective is reflected in its design, including support for technologies and products that are essential inputs to biomanufacturing processes themselves.
Click to download the joint statement
About LSMA
The Life Science Manufacturers Association (LSMA) is the European trade association representing upstream life-sciences manufacturing technology companies. Our members develop and supply the tools, equipment and specialised inputs that enable Europe’s life-sciences ecosystem from discovery through production. We are committed to strengthening Europe’s competitiveness by advancing the conditions required for globally competitive life-sciences manufacturing.
